Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 374

Sort by

Sort Order Select

Journal Articles

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Blood (2024) 144 (20): 2121–2135.

https://doi.org/10.1182/blood.2024024590

Published: 2024

Includes: Supplemental data

Journal Articles

An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma

Katia Grillone, Serena Ascrizzi, Paolo Cremaschi, Jussara Amato, Nicoletta Polerà, Ottavio Croci, Roberta Rocca, Caterina Riillo, Francesco Conforti, Raffaele Graziano, Diego Brancaccio, Daniele Caracciolo, Stefano Alcaro, Bruno Pagano, Antonio Randazzo, Pierosandro Tagliaferri, Francesco Iorio, Pierfrancesco Tassone

Blood (2024) 144 (16): 1705–1721.

https://doi.org/10.1182/blood.2023021991

Published: 2024

Includes: Supplemental data

Journal Articles

KDM6A regulates immune response genes in multiple myeloma

Daphné Dupéré-Richer, Alberto Riva, Benjamin G. Barwick, Sayantan Maji, Heidi Casellas Román, Jianping Li, Umasankar De, Amin Sobh, Gabrielle Quickstad, Crissandra Piper, Marta Kulis, Teresa Ezponda, José Ignacio Martín-Subero, Giovanni Tonon, Weizhou Zhang, Constantine S. Mitsiades, Lawrence H. Boise, Richard L. Bennett, Jonathan D. Licht

Blood (2024) 144 (14): 1508–1520.

https://doi.org/10.1182/blood.2024024518

Published: 2024

Includes: Supplemental data

Journal Articles

NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in multiple myeloma

Eve Blanquart, Rüçhan Ekren, Bineta Rigaud, Marie-Véronique Joubert, Virginie Baylot, Hélène Daunes, Marine Cuisinier, Marine Villard, Nadège Carrié, Céline Mazzotti, Liliana E. Lucca, Aurore Perrot, Jill Corre, Thierry Walzer, Hervé Avet-Loiseau, Pierre-Paul Axisa, Ludovic Martinet

Blood (2024) 144 (12): 1271–1283.

https://doi.org/10.1182/blood.2023023529

Published: 2024

Includes: Supplemental data

Journal Articles

Erdheim-Chester disease in a patient with multiple myeloma

Arthur A. Parsee, Julie Y. Li

Blood (2024) 144 (10): 1131.

https://doi.org/10.1182/blood.2024025514

Published: 2024

Journal Articles

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Blood (2024) 144 (9): 955–963.

https://doi.org/10.1182/blood.2024024041

Published: 2024

Includes: Supplemental data

Journal Articles

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

Blood (2024) 144 (7): 771–783.

https://doi.org/10.1182/blood.2024024299

Published: 2024

Includes: Supplemental data

Journal Articles

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

Blood (2024) 144 (6): 615–628.

https://doi.org/10.1182/blood.2023022823

Published: 2024

Includes: Supplemental data

Journal Articles

Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma

Blood (2024) 144 (4): 402–407.

https://doi.org/10.1182/blood.2023023557

Published: 2024

Includes: Supplemental data

Journal Articles

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Blood (2024) 144 (4): 359–367.

https://doi.org/10.1182/blood.2024024371

Published: 2024

Includes: Supplemental data

Journal Articles

NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome

Blood (2024) 144 (3): 283–295.

https://doi.org/10.1182/blood.2023022859

Published: 2024

Includes: Supplemental data

Journal Articles

IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model

Brandon D. Ng, Adhithi Rajagopalan, Anastasia I. Kousa, Jacob S. Fischman, Sophia Chen, Alyssa Massa, Harold K. Elias, Dylan Manuele, Michael Galiano, Andri L. Lemarquis, Alexander P. Boardman, Susan DeWolf, Jonah Pierce, Bjarne Bogen, Scott E. James, Marcel R. M. van den Brink

Blood (2024) 144 (2): 171–186.

https://doi.org/10.1182/blood.2023022293

Published: 2024

Includes: Supplemental data

Journal Articles

RAS/RAF landscape in monoclonal plasma cell conditions

Blood (2024) 144 (2): 201–205.

https://doi.org/10.1182/blood.2023022295

Published: 2024

Includes: Supplemental data

Journal Articles

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma

Blood (2024) 143 (25): 2612–2626.

https://doi.org/10.1182/blood.2023022777

Published: 2024

Includes: Supplemental data

Journal Articles

Snapper-Schneid bodies (coarse cytoplasmic granules) in a patient with multiply relapsed multiple myeloma

Meredith M. Nichols, Olga Pozdnyakova

Blood (2024) 143 (24): 2559.

https://doi.org/10.1182/blood.2024024221

Published: 2024

Journal Articles

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Blood (2024) 143 (23): 2401–2413.

https://doi.org/10.1182/blood.2023022540

Published: 2024

Includes: Supplemental data

Journal Articles

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma

Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chretien, Lionel Karlin, Martine Escoffre, Caroline Jacquet, Mourad Tiab, Xavier Leleu, Herve Avet-Loiseau, Alexandra Jobert, Lucie Planche, Jill Corre, Philippe Moreau

Blood (2024) 143 (20): 2029–2036.

https://doi.org/10.1182/blood.2023023597

Published: 2024

Includes: Supplemental data

Journal Articles

Smoldering multiple myeloma: taking the narrow over the wide path?

Herve Avet-Loiseau, Nizar J. Bahlis

Blood (2024) 143 (20): 2025–2028.

https://doi.org/10.1182/blood.2024023880

Published: 2024

Journal Articles

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

Blood (2024) 143 (13): 1242–1258.

https://doi.org/10.1182/blood.2023021581

Published: 2024

Includes: Supplemental data

Journal Articles

BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms

Holly Lee, Paola Neri, Nizar J. Bahlis

Blood (2024) 143 (13): 1211–1217.

https://doi.org/10.1182/blood.2023022499

Published: 2024

Includes: Supplemental data

NARROW

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma

KDM6A regulates immune response genes in multiple myeloma

NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in multiple myeloma

Erdheim-Chester disease in a patient with multiple myeloma

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome

IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model

RAS/RAF landscape in monoclonal plasma cell conditions

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma

Snapper-Schneid bodies (coarse cytoplasmic granules) in a patient with multiply relapsed multiple myeloma

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma

Smoldering multiple myeloma: taking the narrow over the wide path?

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only